Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-502 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-502 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ARRY-502 | DRUG | Oral; multiple dose, escalating |
| Placebo | DRUG | Oral; matching placebo |
Key Inclusion Criteria: * Healthy male or female between the ages of 18 and 50 years. * Females must be of nonchildbearing potential. * Body mass index (BMI) of 18 to 32 and a total body weight \> 50 kg (110 lbs) and \< 114 kg (250 lbs). * Additional criteria exist. Key Exclusion Criteria: * Evid...
ARRY-502 is an investigational small molecule being studied for the treatment of persistent asthma. It has also been evaluated in healthy subjects as part of early clinical development. The drug is not approved and remains in clinical trials.
Pfizer, Inc. (NYSE: PFE) is developing ARRY-502. The company has sponsored clinical trials of the drug in healthy subjects and in patients with persistent asthma.
ARRY-502 is in clinical development. It has completed a Phase 1 trial in healthy subjects and a Phase 2 trial in patients with persistent asthma. The drug is investigational and not approved for any use.
ARRY-502 has been studied in two completed trials: NCT01349725, a Phase 1 safety study in healthy subjects, and NCT01561690, a Phase 2 study in patients with persistent asthma. Both trials were conducted in the United States.
No alternative names for ARRY-502 have been disclosed. The drug is referred to solely by its code name ARRY-502 in clinical trial records and by its developer, Pfizer.